First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and ...
Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion ...
Addressing a CII India Reception on the sidelines of the SelectUSA Investment Summit at National Harbour in Maryland on Monday evening, May 4, US Deputy Undersecretary (Policy and International Trade ...
For Indian billionaire Dilip Shanghvi, who made his fortune selling cheap generic drugs to the world, it was clear at least more than a decade ago that a shift toward specialty treatments would be key ...
On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to ...
Organon & Co. recently released its 10-Q report. Organon is a global healthcare company focused on women’s health and general ...
On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, in an all-cash transaction with an estimated value of ...
Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales ...
Post-Organon deal, ICICI Direct downgraded Sun Pharma to Hold, IIFL adjusted to Add, Investec maintained a Sell rating, while JM Financial stayed at Buy but with a cautious "slower orbit" view on long ...
After intense negotiations, Sun Pharma is set to acquire Organon for $11.75 billion, marking a significant milestone for Indian overseas acquisitions. The deal aims to strengthen Sun Pharma's global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results